Search Results - stephany+tzeng

11 Results

Sort By:

Polymeric particles for sustained delivery of multimodal peptide therapeutics

Polymeric particles for sustained delivery of multimodal peptide therapeutics JHU Ref #: C11250 Value Proposition · Stability: polymeric nanoparticle encapsulation increases and sustains peptide residence time, for increased accumulation in tissue vasculature and maximize treatment effects · Safety: use of nanoparticles...

Published: 10/27/2025 | Inventor(s): Jordan Green, Aleksander Popel, Joel Sunshine, Ron Shmueli, Stephany Tzeng, Kristen Kozielski

Keywords(s): Biologics, Drug Delivery Vehicle, Nucleic Acid, Peptide, Polymers, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Dendrimers & Polymers, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Peptides, Technology Classifications > Therapeutic Modalities

Cationic Polymers with Biphasic Biodegradation

Value Proposition· Delivery Efficacy: Demonstrates more effective gene delivery to cancer associated fibroblasts (CAFs) or human primary fibroblasts than industry gold-standards such as Lipofectamine 2000 and polyethylenimine (PEI).· Cargo Compatibility: Enables encapsulation and delivery of a wide range of cargos including, DNA, RNA,...

Published: 10/23/2025 | Inventor(s): Stephany Tzeng, Ron Shmueli, Nupura Bhise, Joel Sunshine, Jordan Green

Keywords(s): Drug Delivery Vehicle, Polymers, Therapeutic Matter, Therapeutics

Polymers and Nanoparticles for Intramuscular Nucleic Acid Delivery

Value Proposition:· Platform technology for prophylactic and therapeutic vaccination with large RNA payloads.· Can deliver several types of nucleic acid payloads including self-amplifying mRNA, plasmid, linear DNA, siRNA, miRNA, mRNA.· Adaptable as a therapeutic delivery strategy for genetic, musculoskeletal, and neurological disorders.Unmet Need:Vaccinology...

Published: 10/24/2025 | Inventor(s): Jordan Green, David Wilson, Stephany Tzeng, Yuan Rui, Sarah Neshat, Kathryn Luly

Keywords(s):

Category(s): Clinical and Disease Specializations > Immunology, Clinical and Disease Specializations > Infectious Diseases

Compositions of Kinetic Nanoparticles containing Nucleic Acids, Polycations, and Lipids with Defined Sizes, and Methods of Producing the Same

Value Proposition:· Scalable, efficient, and tunable nanoparticle creation technique that can deliver a variety of payloads· Polymer-lipid nanoparticles are biodegradable and are being tested for immunogenicity· Can be used for in vivo gene therapy delivery as well as in vitro cell transfection and research applications Technology...

Published: 10/28/2025 | Inventor(s): Hai-Quan Mao, Stephany Tzeng, Jordan Green, Yizong Hu, Sashank Reddy, Leonardo Cheng

Keywords(s):

Polymeric Nanoparticle Genetic Vaccines

Value PropositionVersatile immunotherapy platform with the ability to specifically target antigen presenting cells (APCs) ) following systemic delivery and without requiring targeting ligands to improve treatment efficacy. Flexibility to modulate the immune system through activation or inducing tolerance.Useful as a preventative strategy or therapeutic...

Published: 10/24/2025 | Inventor(s): Jordan Green, Elana Ben-Akiva, Johan Karlsson, Stephany Tzeng, Kelly Rhodes, Sarah Neshat

Keywords(s):

Category(s): Clinical and Disease Specializations > Autoimmunity, Clinical and Disease Specializations > Immunology, Technology Classifications > Medical Devices > Therapeutic Devices, Technology Classifications > Therapeutic Modalities > Dendrimers & Polymers, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities > Vaccines

Polymer-Nucleic Acid Nanoparticles for Gene Editing

Inventors: Jordan J. Green, Stephany Yi Tzeng, Garry R. Cutting, Erin W. Kavanagh Unmet NeedCystic fibrosis (CF) is a progressive, genetic disease that affects the lungs, pancreas, and other organs. There are close to 40,000 children and adults living with cystic fibrosis in the United States (see CFF). In people with CF, mutations in the cystic fibrosis...

Published: 10/24/2025 | Inventor(s): Jordan Green, Stephany Tzeng, Garry Cutting, Erin Kavanagh

Keywords(s):

Category(s): Clinical and Disease Specializations > Fibrosis, Technology Classifications > Therapeutic Modalities > Gene Therapies

Bioreducible Poly(beta-amino ester)s for siRNA Delivery

C12218: Efficient Delivery Vehicle for Controlled Gene Knockdown Novelty: This technology comprises the use of bioreducible polymer based nanoparticle system that can release siRNA cargo to the cytoplasm of cells to knockdown target gene expression in tissues. Value Proposition: Gene therapy is a developing medical field and there is a need for...

Published: 10/23/2025 | Inventor(s): Jordan Green, Stephany Tzeng, Kristen Kozielski

Keywords(s): Biologics, Brain Cancer, Cancers, Cell Therapy, Disease Indication, Drug Delivery Vehicle, Glioma, Nucleic Acid, Polymers, Single, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Gene Therapies, Technology Classifications > Therapeutic Modalities > Cell Therapies, Technology Classifications > Therapeutic Modalities > Dendrimers & Polymers, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Brain Cancer, Clinical and Disease Specializations > Oncology > Glioma

Engineered Tolerogenic Artificial Antigen-presenting Cells for Specific Expansion of Regulatory T Cells

Unmet NeedGlobal incidence of autoimmune disease is on the rise, and currently one in twelve Americans (including one in 9 women) suffer from autoimmune disease. Particularly, Type 1 Diabetes (T1D) represents a highly prevalent autoimmune disease, affecting over 20 million people. These diseases occur when the body’s immune system incorrectly attacks...

Published: 10/24/2025 | Inventor(s): Jordan Green, Jamie Spangler, Stephany Tzeng, Kelly Rhodes, Giorgio Raimondi, Marcos Iglesias Lozano, Jakub Tomala, Derek VanDyke, Randall Meyer

Keywords(s): Autoimmune Diseases, Biologics, Discovery/Research Tools, Disease Indication, Drug Delivery Vehicle, Inflammatory Disorders, Polymers, Recombinant Proteins, Research Reagent, Therapeutic Matter, Therapeutic Substance, Therapeutics, Transplants

Category(s): Clinical and Disease Specializations > Autoimmunity, Clinical and Disease Specializations > Transplantation, Clinical and Disease Specializations > Diabetes > Type 1 Diabetes, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Research Tools, Technology Classifications > Therapeutic Modalities > Cell Therapies

Tolerogenic Artificial Antigen-Presenting Cells

Unmet Need Autoimmune diseases are often treated with immunosuppressants that weaken the entire immune system, leaving patients vulnerable to infection. An ideal autoimmune therapy would establish immune tolerance to a specific self-antigen, while the rest of the immune system remains intact. One promising approach for regulating autoimmunity is via...

Published: 10/24/2025 | Inventor(s): Jordan Green, Kelly Rhodes, Randall Meyer, Stephany Tzeng

Keywords(s): Biologics, Drug Delivery Vehicle, Polymers, Protein, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations > Immunology, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms

Gene Delivery Particles to Induce Tumor-Derived Antigen Presenting Cells

Unmet Need Melanoma is an aggressive form of skin cancer that is characterized by high multidrug resistance and low survival rates. The median survival time for metastatic melanoma patients is approximately 8-9 months with a 3-year overall survival rate of less than 15%. As such, there is a compelling need for novel targeted melanoma therapies. Immunotherapy...

Published: 10/24/2025 | Inventor(s): Jordan Green, Stephany Tzeng, David Wilson, Randall Meyer

Keywords(s): Cancers, Disease Indication, Drug Delivery Vehicle, Nanoparticles, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations > Immuno-Oncology, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities > Immunotherapies

1 2